Medscape www.medscape.com

References for:
Tolterodine, a New Antimuscarinic Drug for Treatment of Bladder Overactivity

[Pharmacotherapy 19(3):267-280, 1999. © 1999 Pharmacotherapy Publications]

  1. National Institutes of Health. Urinary incontinence in adults. National Institutes of Health consensus development conference. J Am Geriatr Soc 1990;38:265-72.
  2. Agency for Health Care Policy and Research. Urinary incontinence in adults: acute and chronic management. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1992.
  3. Fantl JA, Newman DK, Colling J, et al. Urinary incontinence in adults: acute and chronic management. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996.
  4. Hampel C, Wienhold D, Benken N, Eggersmann C, Thuroff JW. Definition of overactive bladder and epidemiology of urinary incontinence. Urology 1997;50(suppl 6A):4-14.
  5. Abroms PH, Blaivas JG, Stanton SL, Andersen JT. Standardization of terminology of lower urinary tract function. Neurourol Urodyn 1988;7:403-27.
  6. Wagner TH, Hu T-W. Economic costs of urinary incontinence in 1995. Urology 1998;51:355-61.
  7. Andersson K-E. The overactive bladder: pharmacologic basis of drug treatment. Urology 1997;50(suppl 6A):74-84.
  8. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996;48:532-65.
  9. Pharmacia & Upjohn. Data on file. Kalamazoo, MI;1998.
  10. Gillberg P-G, Sparf B, Nilvebrant L. Pharmacological in vitro and in vivo profile of DD01 -- a major metabolite of tolterodine [abstr]. Neurourol Urodyn 1996;15:308-9.
  11. Nilvebrant L, Stahl M, Andersson K-E. Interaction of tolterodine with cholinergic muscarinic receptors in human detrusor [abstr]. Neurourol Urodyn 1995;14:523-4.
  12. Nilvebrant L, Glas G, Johnsson A, Sparf B. The in vitro pharmacological profile of tolterodine -- a new agent for the treatment of urinary urge incontinence [abstr]. Neurourol Urodyn 1994;13:433-5.
  13. Nilvebrant L, Andersson K-E, Gillberg P-G, Stahl M, Sparf B. Tolterodine -- a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195-207.
  14. Nilvebrant L, Sundquist S, Gillberg P-G. Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo [abstr]. Neurourol Urodyn 1996;15:310-11.
  15. Gillberg P-G, Modiri A-R, Sparf B. Tolterodine -- a new agent with tissue effect selectivity for urinary bladder [abstr]. Neurourol Urodyn 1994;13:435-6.
  16. Nilvebrant L, Hallen B, Larsson G. Tolterodine -- a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997;13-14:1129-36.
  17. Naerger H, Fry CH, Nilvebrant L. Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders [abstr]. Neurourol Urodyn 1995;14:524-6.
  18. Pharmacia & Upjohn. Detrol (tolterodine) package insert. Kalamazoo, MI;March 1998.
  19. Brynne N, Stahl MMS, Hallen B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther Toxicol 1997;35:287-95.
  20. Ekstrom B, Stahl M, Mattiasson A, Andersson K-E, Sparf B. Effects of tolterodine on bladder function in healthy volunteers [abstr]. J Urology 1995;153(4 suppl):394A.
  21. Stahl MMS, Ekstrom B, Sparf B, Mattiason A, Andersson K-E. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995;14:647-55.
  22. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50(suppl 6A):90-6.
  23. Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol 1998;81:42-8.
  24. Jonas U, Hofner K, Madersbacher H, et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997;15:144-51.
  25. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10.
  26. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.